(Q44086832)

29 November 2017

title

Isolation and characterization of human monoclonal antibodies specific to MMP-1A, MMP-2 and MMP-3. (English)

1 reference

29 November 2017

1 reference

4

1 reference

29 November 2017

Stefanie Pfaffen

1

1 reference

29 November 2017

Teresa Hemmerle

series ordinal

2

1 reference

29 November 2017

Marcel Weber

series ordinal

3

1 reference

29 November 2017

language of work or name

English

0 references

publication date

12 November 2009

1 reference

Experimental Cell Research

29 November 2017

published in

1 reference

29 November 2017

volume

316

1 reference

29 November 2017

issue

5

1 reference

29 November 2017

page(s)

836-847

1 reference

Fully human therapeutic monoclonal antibodies

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

Potent antibody therapeutics by design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

Antibody targeted drugs as cancer therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

Tumour vascular targeting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

Ligand-based vascular targeting of disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

Immunologic and biochemical analysis of TNT-1 and TNT-2 monoclonal antibody binding to histones

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

Phase I study of 131I-chimeric(ch) TNT-1/B monoclonal antibody for the treatment of advanced colon cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

Biodistribution and pharmacokinetics of 125I-labeled monoclonal antibody M75 specific for carbonic anhydrase IX, an intrinsic marker of hypoxia, in nude mice xenografted with human colorectal carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

Matrix metalloproteinases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

The other side of MMPs: protective roles in tumor progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

Matrix metalloproteases: underutilized targets for drug delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

Matrix metalloproteinases: a tail of a frog that became a prince

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

New functions for the matrix metalloproteinases in cancer progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

The Human Protein Atlas--a tool for pathology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

IL-17 stimulates MMP-1 expression in primary human cardiac fibroblasts via p38 MAPK- and ERK1/2-dependent C/EBP-beta , NF-kappaB, and AP-1 activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

Transcriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis: integration of complex signaling pathways for the recruitment of gene-specific transcription factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

A protective role for matrix metalloproteinase-3 in squamous cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

Metastatic potential correlates with enzymatic degradation of basement membrane collagen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

Activity of type IV collagenases in benign and malignant breast disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

Matrix metalloproteinase inhibitors for cancer therapy:the current situation and future prospects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

Keratinocyte expression of MMP3 enhances differentiation and prevents tumor establishment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

Matrix metalloproteinases in tumor progression: focus on basal and squamous cell skin cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

Production of matrix metalloproteinase-2 and metalloproteinase-3 related to malignant behavior of esophageal carcinoma. A clinicopathologic study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

Expression of matrix metalloproteinase-3 in stage I and II squamous cell carcinoma of the oral cavity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

Human collagenase-3 is expressed in malignant squamous epithelium of the skin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

Susceptibility of stromelysin 1-deficient mice to collagen-induced arthritis and cartilage destruction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

The role of stromelysin in the cartilage destruction that accompanies inflammatory arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

Joint destruction in arthritis: metalloproteinases in the spotlight

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

Matrix Metalloproteinase Inhibitors and Cancer--Trials and Tribulations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

Changing views of the role of matrix metalloproteinases in metastasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

Matrix metalloproteinases: biologic activity and clinical implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

Strategies for MMP inhibition in cancer: innovations for the post-trial era.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

Towards third generation matrix metalloproteinase inhibitors for cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

DNA-encoded chemical libraries for the discovery of MMP-3 inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

Continuously recording fluorescent assays optimized for five human matrix metalloproteinases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

Design and use of phage display libraries for the selection of antibodies and enzymes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

Design, construction, and characterization of a large synthetic human antibody phage display library

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

The repertoire of human germline VH sequences reveals about fifty groups of VH segments with different hypervariable loops

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

Antibody-mediated delivery of IL-10 inhibits the progression of established collagen-induced arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

Matrix metalloproteinase-26 is present more frequently in squamous cell carcinomas of immunosuppressed compared with immunocompetent patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

The matrix metalloproteinase/tissue inhibitor of matrix metalloproteinase profile in colorectal polyp cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: New findings and review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

Immunohistochemical analysis of adhesion molecules and matrix metalloproteinases in malignant CNS lymphomas: a study comparing primary CNS malignant and CNS intravascular lymphomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

Making antibodies by phage display technology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

A general method for the selection of high-level scFv and IgG antibody expression by stably transfected mammalian cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

Antibody-mediated delivery of interleukin-2 to the stroma of breast cancer strongly enhances the potency of chemotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

By-passing immunisation. Human antibodies from synthetic repertoires of germline VH gene segments rearranged in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

Comparative immunohistochemistry of L19 and F16 in non-small cell lung cancer and mesothelioma: Two human antibodies investigated in clinical trials in patients with cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

Selective targeting of tumoral vasculature: Comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

Comparative analysis of the membrane proteome of closely related metastatic and nonmetastatic tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

Matrix metalloproteinase 3 is present in the cell nucleus and is involved in apoptosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2009.11.004

10.1016/J.YEXCR.2009.11.004

7 January 2021

Identifiers

DOI

1 reference

29 November 2017

1 reference